Cara Therapeutics – Hot or Not

PUBLISHED: Thu, 07 Sep 2017 04:59:53 GMT
Share


Cara Therapeutics (Nasdaq:CARA) is a clinical-stage biopharmaceutical company which also focuses on pain medication. It has a market cap of $455 million, and is not profitable. Guest Devin Shutte from The Robert Group and resident expert Paul Theron from Vestact decide whether Cara Therapeutics is hot or not.

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.